ZTS
Zoetis Inc.
NYSE · USHealthcareDrug Manufacturers - Specialty & Generic
$76.19-0.48%
Price as of Jul 20, 2026
ZTS financials
Zoetis Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $9.5B | $9.3B | $8.5B | $8.1B |
| Cost of revenue | $2.8B | $2.9B | $2.7B | $2.6B |
| Gross profit | $6.7B | $6.4B | $5.8B | $5.5B |
| Operating expenses | $3.1B | $3.0B | $2.8B | $2.5B |
| Operating income | $3.6B | $3.4B | $3.1B | $2.9B |
| Net income | $2.7B | $2.5B | $2.3B | $2.1B |
| EBITDA | $4.1B | $3.9B | $3.7B | $3.4B |
| Basic EPS | $6.03 | $5.47 | $5.08 | $4.51 |
| Diluted EPS | $6.02 | $5.47 | $5.07 | $4.49 |
| Balance sheet | ||||
| Cash & equivalents | $2.3B | $2.0B | $2.0B | $3.6B |
| Total assets | $15.5B | $14.2B | $14.3B | $14.9B |
| Total liabilities | $12.1B | $9.5B | $9.3B | $10.5B |
| Stockholders’ equity | $3.3B | $4.8B | $5.0B | $4.4B |
| Total debt | $9.5B | $6.7B | $6.8B | $8.1B |
| Net debt | $7.2B | $4.8B | $4.7B | $4.5B |
| Cash flow | ||||
| Operating cash flow | $2.9B | $3.0B | $2.4B | $1.9B |
| Capital expenditure | -$621.0M | -$655.0M | -$732.0M | -$586.0M |
| Free cash flow | $2.3B | $2.3B | $1.6B | $1.3B |
| Dividends paid | -$889.0M | -$786.0M | -$692.0M | -$611.0M |
| Share repurchases | -$3.2B | -$1.9B | -$1.1B | -$1.6B |